Navigation Links
Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update
Date:5/9/2013

LAWRENCEVILLE, N.J., May 9, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the first quarter ended March 31, 2013 and provided a business update on its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.  ThermoDox® is being evaluated in a global, multi-center Phase III clinical trial (the HEAT Study) in patients with non-resectable hepatocellular carcinoma (HCC), also known as primary liver cancer.  ThermoDox® is also being evaluated in a Phase II trial for patients with recurrent chest wall breast cancer, The DIGNITY Study.

Following the announcement on January 31, 2013, that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the HEAT Study's primary endpoint, the Company conducted a comprehensive analysis of the data from the Study which was reviewed by its key principal investigators as well as liver cancer and clinical data experts.  These emerging findings from the HEAT Study suggest that RFA dwell time had a positive impact on progression free survival (PFS) and overall survival (OS) in patients treated with ThermoDox® plus RFA when compared to the control group.  This analysis was conducted in a sizable patient subgroup.  These findings will be discussed by two of the HEAT Study's lead investigators at scientific sessions of the World Conference on Interventional Oncology on May 16, 2013. Celsion's lead investigators agree that these are interesting findings which should be further pursued.

"With the support of our medical advisors, we have been working diligently to better understand the clinical data and findings from the Phase III HEAT Study.  Concurrently, we have been taking appropriate measures to position C
'/>"/>

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013
2. Celsion Corporation Provides Business Update
3. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma
4. Celsion Corporation Announces $15 Million Registered Direct Offering
5. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
6. ETEX Corporation announces extended Supply Agreement with Knee Creations, LLC
7. Verenium Corporation to Announce First Quarter 2013 Financial Results
8. EMCO High Voltage Corporation to Exhibit at 61st ASMS Conference on Mass Spectrometry and Allied Topics
9. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
10. Techne Corporation Releases Unaudited Third Quarter And Nine Month Fiscal Year 2013 Results
11. Street Named After EMCO High Voltage Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  David Hardison, Ph.D., vice president of ... has been elected chairman of the board for ... working to establish common protocols around the use ... to electronic health records. Hardison ... with organizations across the research and health care ...
(Date:7/28/2014)... , July 28, 2014   Propeller Health ... disease, announced the hire of Brad Towle ... will be responsible for driving the company,s sales growth, ... experience in healthcare, and specifically his past role in ... to the company at this pivotal time in the ...
(Date:7/28/2014)... 2014 It’s a hard truth: Nearly half ... further their post-secondary education are failing to obtain a diploma ... year. And according to an analysis by The Resume ... students’ uninformed choice of college majors, which leads to underemployment, ... study: Some 51.7 percent of post-9/11 veterans using GI ...
(Date:7/28/2014)... BRISBANE, Calif. , July 28, 2014  InterMune, ... it will release its second quarter 2014 financial results ... August 6, 2014. A live conference call and webcast will ... that same day. Interested investors and others ... (U.S.) or +1 212-231-2900 (international), conference ID#21728775. A replay of ...
Breaking Biology Technology:ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4InterMune to Release Second Quarter Financial Results on August 6 2
... 2012 Oxford BioTherapeutics (OBT) today announces that ... advisor and non-executive director.  Dr Begley, who was the Vice ... Amgen, will take on a key role in helping shape ... its pipeline of oncology antibody-based drugs into clinical development. ...
... Advanstar Communications, is pleased to announce the agenda for ... held April 26 - 27, 2012 at the Loews ... share their strategies for improving patient outcomes and product ... Conference highlights include: , The ...
... Jan. 11, 2012  goBalto, developer of new generation ... completed a FDA 21 CFR Part 11 compliance ... trials application. Tracker,s successful audit will help both ... running clinical trials comply with FDA rules and ...
Cached Biology Technology:Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director 2Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director 3Complete Agenda Announced for 11th Annual Patient Adherence Forum 2goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit 2
(Date:7/28/2014)... Norwegian explorer Roald Amundsen reached the South Pole in ... arrived long before any human. , Using data from ... the Antarctic continent, including the South Pole, a group ... (DRI) in Reno, Nevada, created the most accurate and ... southernmost continent. The new record, described in an article ...
(Date:7/28/2014)... Yale School of Medicine have pinpointed a mechanism in part ... in the blood, linking it to both type 1 and ... 28 issue of Proceedings of the National Academies of ... enzyme located in a part of the hypothalamus known ... in motion that control glucose levels in the blood," said ...
(Date:7/28/2014)... findings of a new study suggest two ways to effectively ... as well in obese women, compared to women of a ... one-size-fits-all method, researchers say, but as the population has increased ... works for obese women. Studies have consistently found that obesity ... which may in turn affect how well the pill prevents ...
Breaking Biology News(10 mins):Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3Glucose 'control switch' in the brain key to both types of diabetes 2Strategies identified to improve oral contraceptive success with obese women 2
... developed a clever method to purify parasitic organisms from ... proteomic studies and a deeper insight into the biology ... each year. Many infectious pathogens, like those ... have a complex life cycle alternating between free-living creature ...
... carbon dioxide from burning of fossil fuels might be kept below ... next few decades, say researchers. They say that less plentiful oil ... greater supplies of coal mean that it must be the main ... Biogeochemical Cycles . , ...
... addition to social factors when selecting a mate. In ... PLoS Genetics, scientists in China, France, and the ... be involved in mate choice in some human populations. ... Major Histocompatibility Complex (MHC), a large genomic region involved in ...
Cached Biology News:Curbing coal emissions alone might avert climate danger, say researchers 2Curbing coal emissions alone might avert climate danger, say researchers 3
See product name for description....
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
... Serum • Rhesus serum is collected from ... years of age. Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Porcine Serum US Origin 6 Months or Older...
Biology Products: